4//SEC Filing
Glenn Gregory M 4
Accession 0001209191-23-018545
CIK 0001000694other
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 5:16 PM ET
Size
15.2 KB
Accession
0001209191-23-018545
Insider Transaction Report
Form 4
NOVAVAX INCNVAX
Glenn Gregory M
Chief Scientific Officer
Transactions
- Purchase
Common Stock
2023-03-06$7.48/sh+3,000$22,454→ 11,473 total - Tax Payment
Common Stock
2023-03-10$6.52/sh−2,432$15,857→ 18,339 total - Purchase
Common Stock
2023-03-07$7.04/sh+2,000$14,088→ 13,473 total - Exercise/Conversion
Common Stock
2023-03-10$6.52/sh+6,298$41,063→ 20,771 total - Purchase
Common Stock
2023-03-10$6.50/sh+1,000$6,500→ 14,473 total - Exercise/Conversion
Restricted Stock Units
2023-03-10−6,298→ 12,596 total→ Common Stock (6,298 underlying)
Footnotes (7)
- [F1]The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- [F2]Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.
- [F3]The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- [F4]The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- [F5]The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
- [F6]Each RSU represents a contingent right to receive one share of the Company common stock.
- [F7]The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.
Documents
Issuer
NOVAVAX INC
CIK 0001000694
Entity typeother
Related Parties
1- filerCIK 0001342823
Filing Metadata
- Form type
- 4
- Filed
- Mar 13, 8:00 PM ET
- Accepted
- Mar 14, 5:16 PM ET
- Size
- 15.2 KB